drugset / Trial / NCT03101930
Cardiovascular Effects of GLP-1 Receptor Activation
Phase 4
Completed
329 enrolled
Vanderbilt University Medical Center
American Heart Association · collab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual factors that modulate GLP1R sensitivity can modify the effect of these analogues on cardiovascular risk.
Timeline
- Start
- 2017-05-01
- Primary completion
- 2021-06-24
- Completion
- 2021-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avexitide | Peptide | — | — |
| Subject | Liraglutide | Peptide | 1.8 mg | Subcutaneous |
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |